ApTOLL is under clinical development by AptaTargets and currently in Phase II for Acute Ischemic Stroke. According to GlobalData, Phase II drugs for Acute Ischemic Stroke have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ApTOLL’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ApTOLL (ApTLR-4FT) is under development for the treatment of acute ischemic stroke, Intracerebral hemorrhage, myocardial infarction, multiple sclerosis, inflammation and coronavirus disease 2019 (COVID-19). It is administered as an intravenous infusion. The drug candidate is an aptamer which acts by targeting TLR-4 (Toll-Like receptor-4).
AptaTargets is a biopharmaceutical company that develops therapeutic applications based on aptamer technology. The company’s products are used for the treatment of acute stroke, hemorrhage, acute myocardial infarction, multiple sclerosis, among others. Apta Targets carters in neuroprotection and immune modulation. Its aptamers are chemically synthesized alternatives of antibodies and feature highly reproducibility, stability at room temperature, and low immunogenicity. The company is a developing in aptatargets, aptoll and targeting indications. AptaTargets is headquartered in Madrid city, Madrid, Spain.
For a complete picture of ApTOLL’s drug-specific PTSR and LoA scores, buy the report here.